Borlaug, B. A. et al. Obesity and heart failure with preserved ejection fraction: new insights and pathophysiological targets. Cardiovasc. Res. 118, 3434–3450 (2023).
Kosiborod, M. N. et al. Semaglutide in patients with heart failure with preserved ejection fraction and obesity. N. Engl. J. Med. 389, 1069–1084 (2023).
Kosiborod, M. N. et al. Semaglutide in patients with obesity-related heart failure and type 2 diabetes. N. Engl. J. Med. 390, 1394−1407 (2024).
Packer, M. et al. Tirzepatide for heart failure with preserved ejection fraction and obesity. N. Engl. J. Med. 392, 427–437 (2025).
Cohen, C., Cohen, R. & Sabouret, P. Semaglutide, obesity-related heart failure, and type 2 diabetes. N. Engl. J. Med. 391, 380 (2024).
Bliddal, H. et al. Once-weekly semaglutide in persons with obesity and knee osteoarthritis. N. Engl. J. Med. 391, 1573–1583 (2024).
Verbrugge, F. H., Guazzi, M., Testani, J. M. & Borlaug, B. A. Altered hemodynamics and end-organ damage in heart failure: impact on the lung and kidney. Circulation 142, 998–1012 (2020).
Borlaug, B. A., Sharma, K., Shah, S. J. & Ho, J. E. Heart failure with preserved ejection fraction: JACC Scientific Statement. J. Am. Coll. Cardiol. 81, 1810–1834 (2023).
Litwin, S. E. et al. Exercise-induced left atrial hypertension in heart failure with preserved ejection fraction. JACC Heart Fail. 11, 1103–1117 (2023).
Sayed, A., Vasan, R. S., Harrell Jr., F. E. & Butler, J. Trends in the prevalence, associated risk factors, and health burden of heart failure in the United States, 1988 to 2023. J. Am. Coll. Cardiol. 86, 2542−2564 (2025).
Redfield, M. M. & Borlaug, B. A. Heart failure with preserved ejection fraction: a review. JAMA 329, 827–838 (2023).
Thomas, J., Dagan, M., Wang, B., Gutman, S. & Kaye, D. M. Mechanisms of GLP-1 receptor agonists in HFpEF: exploring weight-dependent and independent drivers of therapeutic benefit. Circ. Heart Fail. 19, e013279 (2026).
Borlaug, B. A. et al. Cardiac and metabolic effects of dapagliflozin in heart failure with preserved ejection fraction: the CAMEO-DAPA trial. Circulation 148, 834–844 (2023).
Feldman, T. et al. Transcatheter interatrial shunt device for the treatment of heart failure with preserved ejection fraction (REDUCE LAP-HF I [Reduce Elevated Left Atrial Pressure in Patients With Heart Failure]): a phase 2, randomized, sham-controlled trial. Circulation 137, 364–375 (2018).
Burkhoff, D. et al. Levosimendan improves hemodynamics and exercise tolerance in PH-HFpEF: results of the randomized placebo-controlled HELP trial. JACC Heart Fail. 9, 360–370 (2021).
Gopalasingam, N. et al. Randomized crossover trial of 2-week ketone ester treatment in patients with type 2 diabetes and heart failure with preserved ejection fraction. Circulation 150, 1570–1583 (2024).
Obokata, M., Reddy, Y. N., Pislaru, S. V., Melenovsky, V. & Borlaug, B. A. Evidence supporting the existence of a distinct obese phenotype of heart failure with preserved ejection fraction. Circulation 136, 6–19 (2017).
Sorimachi, H. et al. Pathophysiologic importance of visceral adipose tissue in women with heart failure and preserved ejection fraction. Eur. Heart J. 42, 1595–1605 (2021).
Pandey, A. et al. Weight loss, exercise haemodynamics, and health status with incretin therapy for heart failure with preserved ejection fraction and obesity. Eur. Heart J. 47, 5593−5596 (2026).
Borlaug, B. A. et al. Semaglutide in HFpEF across obesity class and by body weight reduction: a prespecified analysis of the STEP-HFpEF trial. Nat. Med. 29, 2358–2365 (2023).
Borlaug, B. A. et al. Impact of body mass index, central adiposity, and weight loss on the benefits of tirzepatide in HFpEF: the SUMMIT trial. J. Am. Coll. Cardiol. 86, 242–255 (2025).
Obokata, M., Reddy, Y. N. V., Melenovsky, V., Pislaru, S. & Borlaug, B. A. Deterioration in right ventricular structure and function over time in patients with heart failure and preserved ejection fraction. Eur. Heart J. 40, 689–697 (2019).
Zile, M. R. et al. Relationship between remote, ambulatory pulmonary artery pressures, and all-cause mortality in patients with chronic heart failure. Circ. Heart Fail. 18, e012754 (2025).
Wang, N. et al. Blood pressure-lowering efficacy of antihypertensive drugs and their combinations: a systematic review and meta-analysis of randomised, double-blind, placebo-controlled trials. Lancet 406, 915–925 (2025).
Ostrominski, J. W. et al. Adiposity-related anthropometrics and clinical outcomes in heart failure with mildly reduced or preserved ejection fraction: a participant-level pooled analysis of randomized clinical trials. J. Am. Coll. Cardiol. 86, 1760–1777 (2025).
Borlaug, B. A., Melenovsky, V. & Koepp, K. E. Inhaled sodium nitrite improves rest and exercise hemodynamics in heart failure with preserved ejection fraction. Circ. Res. 119, 880–886 (2016).
Borlaug, B. A., Koepp, K. E. & Melenovsky, V. Sodium nitrite improves exercise hemodynamics and ventricular performance in heart failure with preserved ejection fraction. J. Am. Coll. Cardiol. 66, 1672–1682 (2015).
Kazui, S. et al. Cardiac and metabolic effects of semaglutide in obesity-related heart failure with preserved ejection fraction: rationale and design of the CAMEO-SEMA trial. JACC Heart Fail. (in the press).
